Inovio Pharmaceuticals’ (INO) “Neutral” Rating Reiterated at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 76.47% from the company’s current price.

Several other equities research analysts also recently weighed in on INO. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 27th. Piper Sandler initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They issued an “overweight” rating and a $5.00 target price for the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. Finally, Oppenheimer decreased their target price on Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.80.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ:INO opened at $1.70 on Thursday. The firm has a market capitalization of $62.34 million, a PE ratio of -0.65 and a beta of 1.38. The business has a 50-day moving average of $1.69 and a two-hundred day moving average of $1.84. Inovio Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $8.13.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.02. As a group, research analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Nomura Holdings Inc. purchased a new position in Inovio Pharmaceuticals in the first quarter valued at about $28,000. Alpine Global Management LLC bought a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $31,000. Catalyst Funds Management Pty Ltd bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $35,000. Freedom Investment Management Inc. bought a new position in Inovio Pharmaceuticals during the 1st quarter worth approximately $31,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.